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A B S T R A C T
Immunological abnormalities have been demonstrated in several psychiatric disorders. Predominantly, studies
have focused on younger adults, and research on elderly psychiatric in-patients is scant. In this naturalistic study,
we investigated changes in cytokine levels during the treatment of diagnostically unselected elderly psychiatric
in-patients, and whether these changes could be related to clinical outcomes. Clinical variables, demographic
data, lifestyle data, and blood samples, including 27 plasma cytokines representing a broad spectrum of in-
flammatory mediators, were collected from 81 patients, 60 years and older, at admission and discharge. A
subgroup of 49 patients also completed a self-reported clinical, psychiatric status form, indicating their level of
recovery during hospitalisation. Statistical analyses demonstrated that a broad range of cytokines fell during
treatment, and the fall was associated with clinical improvement, irrespective of psychiatric and somatic di-
agnoses. Exploiting cytokines as biomarkers of clinical traits might to be of limited use in a general population of
elderly psychiatric in-patients as the field stands now.
1. Introduction
Immunological dysfunction, including aberrant cytokine levels, has
been demonstrated as an integral part of several psychiatric disorders,
spanning from depression to autism (Bjorklund et al., 2016; Leighton
et al., 2018; Trepanier et al., 2016). Specific cytokine patterns have also
been suggested to provide clues to diagnoses, staging, treatment and
prognosis (Black and Miller, 2015; Tatay-Manteiga et al., 2017).
However, most of these studies do not include elderly psychiatric pa-
tients, and in particular elderly psychiatric in-patients, despite their
growing importance due to the aging populations in most countries
(Beard et al., 2016) and the high degree of health care utilization
amongst elders (Ilinca and Calciolari, 2015). Furthermore, the studies
have often been restricted to delineated psychiatric disorders, excluding
patients with comorbid conditions. Though this might be considered
beneficial from a methodological perspective, it leaves the question as
to whether the research is relevant for the clinician working with
elderly co-morbid psychiatric patients. A related issue is the naturally
occurring age-related change in immunological competence, so-called
immunosenescence or immune-aging (Weinberger, 2017). Accordingly,
neuroinflammatory studies on younger adults are not necessarily ap-
plicable to elderly psychiatric patients (Bugge et al., 2018).
In this naturalistic study, we investigated changes in cytokine levels
during the treatment of diagnostically unselected elderly psychiatric in-
patients, and whether these changes could be related to clinical out-
comes.
2. Material and methods
2.1. Ethics approval and consent to participate
All patients were presented oral and written information about the
study. Consentual competency was assessed according to established
guidelines (Pedersen et al., 2007). For patients who were considered
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unable to give individual consent due to their medical and/or psy-
chiatric condition, information about the study was provided to their
next of kin. All patients, and their next of kin when relevant, had to sign
a written consent in order to participate in the study. Approval of the
study was obtained from the Regional Committee for Medical and
Health Research Ethics of Northern Norway (REC North, reg. nr. 2009/
1388).
2.2. Declaration of interest
Declaration of interest: none.
2.3. Population
Eighty-one diagnostically unselected patients, 60 years and older,
consecutively admitted to a psychiatric hospital in Tromsø, Norway
(69 °N), during an 18-month period, were selected for inclusion. The
patients were drawn from a catchment area of approximately 250 000
citizens. Patients that could not communicate or cooperate, for instance
due to delirium or severe dementia, were excluded from the study, as
were patients with medical conditions that could significantly distort
inflammatory parameters, such as an ongoing infection or severe de-
hydration. Five eligible patients declined to participate, and two pa-
tients were excluded due to medical reasons. Demographic data, life-
style data, clinical variables and routine blood samples including
electrolytes, liver enzymes, blood cells and thyroid hormones were
collected form all patients. In addition, 27 plasma cytokines re-
presenting a broad spectrum of inflammatory mediators were analysed
at admission and discharge. At discharge, 49 patients (60% of all pa-
tients) completed a self-reported clinical, psychiatric status form, with
five categories: Complete recovery, Almost complete recovery, Partial
recovery, No recovery and Worsening.
2.4. Cytokines
Within the first three days after admittance, and at the day of dis-
charge, morning blood samples were collected from all patients. Plasma
for cytokine analysis were obtained from blood collected into EDTA-
tubes, immediately placed on crushed ice, centrifuged, and rapidly
frozen to -70 °C, until analysed in one batch, using an immunoassay
method, i.e. a Multiplex Analyser with a predefined kit (Bio-Plex
Human Cytokine 27-Plex Panel; Bio-Rad Laboratories Inc., Hercules,
CA). The following cytokines were analysed: IL-1β, IL-1 receptor an-
tagonist (IL1-ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12
(p70), IL-13, IL-15, IL-17, eotaxin, basic fibroblast growth factor
(bFGF), granulocyte-colony stimulating factor (G-CSF), granulocyte
macrophage colony stimulating factor (GM-CSF), interferon (IFN)-γ,
interferon-inducible protein (IP-10), monocyte chemotactic protein
(MCP-1), macrophage inflammatory protein (MIP-1α, MIP-1β), platelet
derived growth factor-BB (PDGF-BB), regulated upon activation T cell
expressed and secreted (RANTES), tumour necrosis factor (TNF), and
vascular endothelial growth factor (VEGF).
Two cytokines, GM-CSF and IL-15, had a high frequency of non-
detectable levels. Consequently, these cytokines were excluded from
further statistical analyses. An additional eight cytokines had a small
number of patients with cytokine levels below the lower detection limit
(number of patients with non-detectable levels): IL-2 (4), IL-10 (11), IL-
13 (1), IL-17 (4), bFGF (2), G-CSF (2), PDGF-BB (2), and VEGF (4). In
order to include these patients in the statistical analyses, data were
imputed using SPSS, see the Statistical analyses section.
2.5. Clinical assessment
A battery of psychometric instrument were used in the clinical as-
sessment of the patients (N= number of patients): the MINI
International Neuropsychiatric Interview (Sheehan et al., 1998),
N= 52, the Mini-Mental State Examination/MMSE (Folstein et al.,
1975), N= 76, the Clockdrawing Test (Tuokko et al., 1992), N= 74,
the Montgomery and Aasberg Depression Rating Scale/MADRS
(Montgomery and Asberg, 1979), N= 60, or the Cornell Scale for De-
pression in Dementia (Alexopoulos et al., 1988), N= 20. The psycho-
metric tests were applied at the discretion of the clinicians, based on the
state and cooperability of the patient. Nevertheless, the majority of
patients (N= 80) underwent at least one psychometric interview on
depression and one test of cognitive impairment. In addition, experi-
enced clinicians conducted standardized clinical interviews and reviews
of medical records in assessment and diagnostics. When appropriate,
interviews of next of kin were also undertaken. All patients were di-
agnosed according to the ICD-10 research criteria.
2.6. Treatment
Patients were treated with a combination of predominantly sup-
portive psychotherapy, psychoeducation and biological treatment, in-
cluding psychotropic medication. Table 1 provides an overview of the
given biological treatment.
2.7. Statistical analyses
As demonstrated by a Kolmogorov-Smirnov test, the data were not
strictly normally distributed. Accordingly, the Spearman rank correla-
tion coefficient was used to analyse differences between the rankings of
two variables. A chi-square test was applied to determine if there was a
significant difference between two sets of data (Pearson Chi-square,
asymptomatic 2-sided). To test deviations from a theoretically expected
distribution of a dichotomous variable, a binominal test was used. Due
to multiple statistical analyses, false detection rate adjusted p-values
(FDR-p) were calculated and applied to all analyses related to the cy-
tokines. IBM Statistical Package for the Social Sciences, Version 23
(SPSS Inc., Chicago, Illinois, USA) software was used in the statistical
analysis.
As mentioned in the Cytokine section, a small group of patients had
very low or undetectable levels of eight cytokines, i.e. the analyser
could not determine the cytokines levels in these patients; they were so-
called non-detects (NDs). This is a normal finding for several cytokines
in healthy adults. Accordingly, data from these patients should not be
reported as missing data, as they might provide valuable statistical
information. For the purpose of including these patients in the statis-
tical analyses, we did single imputations, i.e. using the random number
generator of SPSS, we substituted the NDs with a random, uniformly




Patients were referred by general practitioners for various psy-
chiatric conditions, depression (54%), psychosis (17%) and dementia
Table 1
Biological treatment during hospitalization.
Drugs Number of patients Percentage of patients
Antidepressants 54 67
Antipsychotics 40 49
Antidepressants+ antipsychotics 26 32
Mood stabilizers 2 3
Paracetamol, Ibuprofen 13 16
Acetylsalicylic acid (low dose) 25 31
Steroids, cytostatic agent 8 10
Electroconvulsive therapy 12 15
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(11%) being the most common. Women represented the majority of
patients (61%). Median age was 76 year (SD 7.5). About half of the
patients had undergone previous psychiatric hospitalization (47%), and
a quarter of patients had two or more preceding hospitalizations. Most
patients had a somatic disease (78%), cardiovascular disease being the
most frequent (30%). The mean duration of admission was 39 days
(median=34 days).
Compared to the total population (N=81), the population that
completed the psychiatric status form at discharge (N=49), henceforth
the outcome population, had a higher proportion of female patients
(71%), somewhat more patients with previous psychiatric hospitaliza-
tion (57%) and patients with somatic disease (88%), but had otherwise
comparable characteristics.
3.2. Diagnoses
The major diagnostic categories in the main population and the
outcome population after assessment are shown in Table 2. The most
common diagnosis in both populations was recurrent depressive dis-
order, though relatively more common in the outcome population
(39%, versus 30% in the main population). The second most common in
the main population was dementia in Alzheimer’s disease (24%). In the
outcome population, the second most common diagnosis was bipolar
affective disorder (10%).
3.3. Self-reported clinical status
For analysing purposes, the five categories of the self-reported
clinical, psychiatric status form, were combined into two main cate-
gories: Improvement (69% of patients, N= 49), containing patients
who rated their status at discharge as Complete recovery (23%) and
Almost complete recovery (46%), and Little/No improvement (31% of
patients, N=49), containing patients who rated their status at dis-
charge as Partial recovery (21%), No recovery (8%) and Worsening
(2%).
3.4. Changes in cytokine levels in the total population during treatment
In the total population (N=81), there was a fall in cytokine levels,
as median values fell for 19 cytokines and rose for three cytokines,
whereas three cytokines were unchanged (Table 3). When categorizing
each cytokine into two groups, Rise or Fall, depending on whether the
majority of patients had a rise or fall in that cytokine, 20 cytokines were
classified in the Fall-category, with a difference in median between rise
and fall of 35% (difference calculated as a percentage of total number of
patients, N=81). The remaining five cytokines were classified in the
Rise-category, with a difference in median between rise and fall of 9%
(Fig. 1). Thus, most patients had a fall in cytokine levels during hos-
pitalization, and the fall was more extensive than for the minority of
patients that had a rise in cytokines.
Looking at the outcome population (N=49), patients in the
Improvement-group were more likely to have a fall in cytokine levels,
than in the Little/no-improvement group (p < 0.032). Moreover, there
was a positive correlation between clinical improvement and falling
cytokine levels (p < 0.033) (Table 4).
We did not find any significant difference in the distribution of the
Little/No improvement patients among the rise and fall-category of
individual cytokines. There was however, a significant difference in the
distribution of Improvement patients, i.e. for 11 cytokines there was a
majority of patients with clinical improvements in the fall-category
(FDR-p): IL-17 (0.005), MIP-1α (0.007), INF-γ (0.009), MCP-1 (0.011),
IL-6 (0.014), bFGF (0.016), IL-9 (0.018), PDGF-BB (0.020),G-CSF
(0.023), IL-7 (0.025), IL-5 (0.027).
Adjusting for multiple analyses in the study population (N=81),
we did not find any statistical significant correlations (Spearman rho)
between changes in plasma levels of any single cytokine during ad-
mission, and gender, age, marital status, psychiatric diagnosis, anti-
inflammatory drugs, psychotropic drugs, electroconvulsive therapy,
reason for admittance, smoking, vitamin supplements, alcohol con-
sumption, length of stay, somatic disease, MADRS, MMSE and BMI.
Likewise, we found no correlation between change in any single cyto-
kine and self-reported clinical status at discharge.
4. Discussion
To the best of our knowledge, this the first study to explore changes
in cytokine levels in a group of diagnostically unselected ger-
ontopsychiatric patients in intramural treatment.
The main findings were, first, that for the majority of cytokines the
plasma levels fell during hospitalization, indicating a reduction in in-
flammation, and second, in the outcome subpopulation, almost 70% of
Table 2
Distribution of major diagnostic categories.
Diagnoses ICD-10 Main
population (N=81) %
Outcome population (N=49) %
Organic, including symptomatic, mental disorders F00-09 38 20
Mental and behavioural disorders due to psychoactive substance abuse F10-19 1 2
Schizophrenia, schizotypal and delusional disorders F20-29 12 16
Affective disorders F30-39 41 53
Neurotic, stress-related and somatoform disorders F40-48 7 8
Table 3










IL-12 28.0 −9.6 −34
IP-10 1077 −368 −34
MCP-1 20 −6.7 −34
IL-17 43 −13 −32
RANTES 6767 −1 950 −29
IL-13 7.0 −2.0 −29
MIP-1a 11 −3.0 −27
Eotaxin 96 −23 −24
IL-10 8.0 −2.0 −25
PDGF-BB 138 31 −23
IL-5 5.0 −1.1 −22
IL-9 18 −3.0 −17
MIP-1b 45 −6.0 −13
INF-g 184 −23 −13
IL-7 21 −1.7 −8
bFGF 46 −3.1 −7
G-CSF 53 −3.0 −6
VEGF 22 −1.0 −5
TNF-a 92 −2.0 −2
IL-1ra 154 3.0 2
IL-8 13 1.0 8
IL-2 9.0 1.0 11
IL-4 3.0 0.0 0
IL-6 11 0.0 0
IL-1b 3.0 0.0 0
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the patients reported clinical improvement accompanied with a re-
duction in cytokines during the hospital stay. Thus, on a group level,
there seems to be a correlation between clinical improvement and
falling cytokines. On the other hand, we did not find significant cor-
relations between change in any single cytokine and clinical improve-
ment. Neither did we find significant correlations between cytokine
changes and the various demographic and clinical variables, including
diagnosis.
In principle, the treatment-related drop in cytokines seems to cor-
respond to previous studies in both elderly and younger adults (Dahl
et al., 2014; Hannestad et al., 2011; Hestad et al., 2003; Moreira et al.,
2015; Tuglu et al., 2003). However, these studies have predominantly
focused on selected cytokines in delineated psychiatric disorders,
whereas the cytokine changes in our study appear to be broad-based
and without any demonstrable patternicity. Pertaining to the latter,
earlier research has hypothesised that specific cytokine patterns might
provide markers of diagnosis, treatment options and prognosis
(Goldsmith et al., 2016; Maes et al., 2012; Pedrini et al., 2012). Though
this might be true at specific stages for some psychiatric disorders in
younger adults, our study suggests that cytokine changes are wide-
spread and non-specific in elderly psychiatric patients, perhaps due to
the presence of several conditions. Multimorbidity, defined as the co-
existence of more than two chronic diseases, is common in the elderly,
with a prevalence of more than 60% for those aged 65–74 years and
more than 80% for those aged ≥85 years (Salive, 2013). In our po-
pulation, almost 78% of the patients had a comorbid somatic disorder,
and more than 90% of these patients had more than one somatic dis-
order, i.e. several potential sources of inflammation. The picture is
further complicated by the use of drugs with possible im-
munomodulatory effects (Baumeister et al., 2016), and by age-related
immunological changes and variability (de Groot et al., 2004; Santoni
et al., 2015). Consequently, exploiting cytokines as biomarkers of
clinical traits might to be of limited use in a general population of el-
derly psychiatric in-patients as the field stands now. Likewise, the
outcomes from our study indicate that extrapolating results from re-
search on younger subjects to elderly patients, is a somewhat precarious
undertaking.
The heterogeneity and the size of our population calls for caution
when interpreting the results. The lack of a control group also re-
presents a limitation of the study. Moreover, it should be noted that
single imputation of data to substitute NDs (see the Statistical analysis
section) could lead to skewed statistics, but analyses without the NDs
Fig. 1. Percentage change in cytokine level.
Table 4
Cytokine fall/rise in patients with Little/No improvement and Improvement
(N=49)*.




12 (52 %) 11 (48 %) 23**
Improvement 5 (22 %) 18 (78 %) 23***
Total 17 (37%) 29 (63 %) 46
Pearson Chi-square 4.572 p < 0.032 (asymptomatic 2-sided, df= 1)
Spearman’s rho 0.315 p < 0.033 (2-tailed) p < 0.033 (2-tailed)
* 25 cytokines analysed in each of the two clinical outcome groups.
** Two cytokines with equal number fall/rise excluded (VEGF, IL-8).
*** Two cytokines with equal number fall/rise excluded (IL-1ra, TNF-α).
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did not produce any significant change. We did not perform power
analyses in advance, but in an exploratory study such as ours, power
analyses are notoriously difficult. Furthermore, use of high-sensitivity
C-reactive protein could have provide complementary information
about the inflammatory processes. Finally, we did not have information
about use of statins, a group of drugs known to exhibit anti-in-
flammatory and immunomodulary effects.
Clearly, the complexity of inflammatory processes in elderly psy-
chiatric patients with comorbid disorders is difficult to untangle. This is
not unique to the elderly, though, as we still have not mapped out the
inflammatory mechanisms behind systemic cytokine changes in psy-
chiatric disorders. Hence, more research is needed on both elderly and
younger adults, including healthy individuals and individuals with
psychiatric disorders. Longitudinal studies, including genomic and
proteomic methodology, could also help to shed light upon the neu-
roimmunological processes that take place during the course of a psy-
chiatric illness.
5. Conclusions
A broad range of cytokines fall during treatment of elderly psy-
chiatric in-patients with multimorbidity, and the fall seem to correlate
with clinical improvement, irrespective of psychiatric and somatic di-
agnoses.
All patients were presented oral and written information about the
study. Consentual competency was assessed according to established
guidelines (Pedersen et al., 2007). For patients who were considered
unable to give individual consent due to their medical and/or psy-
chiatric condition, information about the study was provided to their
next of kin. All patients, and their next of kin when relevant, had to sign
a written consent in order to participate in the study. Approval of the
study was obtained from the Regional Committee for Medical and
Health Research Ethics of Northern Norway (REC North, reg. nr. 2009/
1388).
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